Aromyx Corporation

Digitizing the sense of smell

  • Stage $500K in TTM Revenue
  • Industry Software
  • Location Palo Alto, CA, US
  • Currency USD
  • Founded May 2014
  • Employees 14
  • Incorporation Type C-corp
  • Website

Company Summary

Aromyx is a Stanford StartX & DARPA-backed, pre-Series A company with CRISPR-constructed proprietary sensing and AI that digitizes the human sense of smell and taste. We use it to dramatically increases yields in biologic drug fermentation and production, where we have a $250,000 R&D program with one of the largest pharma companies. We use it in agriculture, where we have a similar-sized pilot program with one of the largest ag companies.


  • IBM, Seagate, DOD, NSA, 4 prior startups, 2 successful exits. Track record of large sales. Stanford University BA, MA. Helped start cognitive computing development at IBM. Put together government research funding for the IBM Research program to reverse engineer the human brain, and to design and build a chip that mimics synapses in the human brain. Led commercialization efforts for the new neurosynaptic 'brain' chip and software infrastructure.

  • 85a972d7 6593 41e6 bafd 5eb7b3075302
    Board member, inventor of the chip

    SRI, prior startups, inventor of this biosensor. Has also founded companies, most notably Target Discovery, a successful biotech firm.

  • De58a2b3 8032 479f a6bb 7b63fd73ae30
    Chief Scientific Officer

    Dr. Bill Harries, our Chief Scientist, was before Aromyx the acting chief scientific officer of the Center for Structures of Membrane Proteins (CSMP) at the University of California San Francisco, where he was responsible for developing state of the art membrane protein expression, purification, crystallization, and structure determination methods and instrumentation.

  • Ed
    Vice President, Engineering

    Has been building complex systems and the software that drives them for over 20 years. Most recently, he has led large-scale programs at Adobe Systems and at HP.

  • Dd11a329 2dfc 417c a189 58997da7ffe0
    Board member

    Biotech entrepreneur, former VC with Sequel Ventures, Guidant, Bayer Pharmaceuticals.

  • Default avatar
    Dr. Danny Dhanasekaran
    Science Advisor

    Dr. Dhanasekaran has led groundbreaking research teams in the study of the biology and behavior of olfactory receptors. He serves as Director of the Center for Basic Cancer Research at Oklahoma University Cancer Institute and Editor-in-Chief of the Journal of Molecular Signaling. He is also a professor in the cell biology department in the University of Oklahoma College of Medicine at the OU Health Sciences Center.

  • Default avatar
    Todd Cushman
    Vice President, Sales

    15 years IT, data, software, pharma sales to large accounts. IBM, Zeneca Pharmaceuticals.

  • Default avatar
    Dr. James Broach
    Science Advisor

    Dr. Broach pioneered seminal work in the science and biology of olfaction. He is Chair of the Department of Biochemistry and Molecular Biology at Penn State Hershey, Director of the Penn State Institute for Personalized Medicine and Professor Emeritus of Princeton University.

  • Default avatar
    Dr. Robert Stroud
    Science Advisor

    Professor of Biochemistry & Biophysics , Professor of Pharmaceutical Chemistry , member of the Macromolecular Structure Group, Department of Biochemistry & Biophysics at the University of California San Francisco.


  • C66c19be b5ea 43bd 9ea9 25ce1ba50810
    VC, Board Member of Tivo, Daily Mail and General Trust, Educator, Recovering Entrepreneur. Currently venture partner at Draper Fisher Jurvetson.
    3ad629c7 67e8 4ddd b66a 1bb05318a643
    Professor of Food Chemistry, Oregon State University
    7d0db451 8b12 434a 98d7 d62e67ee1d1f
    Smell scientist, consultant, and author
  • E47ff244 ea4a 45bd b1d7 cd438cde75f5
    Consulting Winemaker
    459b5f2c c262 4494 bc10 d592070f2f49

Previous Investors